Hirschfield G, Boudes P, Bowlus C, Gitlin N, Michael G, Harrison S, Gordon SC, Aspinall R, Doerffel Y, Kremer A, Sheridan D, Bacon B, Berg C, Borg B, Hassanein T, Odin J, Shiffman M, Thuluvath PJ, Thorburn D, Bernstein D, Buggisch P, Corless L, Levy C, Mayo MJ, Swain MG, Vierling J, Woerns MA, Steinberg AS, Bergheanu S, Choi YJ, Varga M, Martin R, Mcwherter C, Jones D (2018)
Publication Type: Conference contribution
Publication year: 2018
Publisher: ELSEVIER SCIENCE BV
City/Town: AMSTERDAM
Pages Range: S105-S106
Conference Proceedings Title: JOURNAL OF HEPATOLOGY
DOI: 10.1016/s0168-8278(18)30429-x
APA:
Hirschfield, G., Boudes, P., Bowlus, C., Gitlin, N., Michael, G., Harrison, S.,... Jones, D. (2018). Treatment efficacyand safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12-and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study. In JOURNAL OF HEPATOLOGY (pp. S105-S106). Paris, FR: AMSTERDAM: ELSEVIER SCIENCE BV.
MLA:
Hirschfield, G., et al. "Treatment efficacyand safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12-and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study." Proceedings of the International Liver Congress (ILC), Paris AMSTERDAM: ELSEVIER SCIENCE BV, 2018. S105-S106.
BibTeX: Download